Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA-I&T vs ARPI in metastatic hormone-sensitive prostate cancer
2022-500570-33-00Phase 3Authorised
- Sponsor
- Region Västerbotten
- Start
- May 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lutetium Lu 177 PSMA I&T, apalutamide, enzalutamide and abiraterone in prostate cancer (PCa) (2 arms), sponsored by Region Västerbotten. Primary endpoint: Progression-free survival. Planned start May 2023; status: authorised.
02
Drugs
lutetium Lu 177 PSMA I&Tapalutamideenzalutamideabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-500570-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500570-33-00.